You are here

  • Home
  • Archive
  • Volume 10, Issue 10
  • Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Article metrics

Article menu
XML
Neurology
Original research
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

 

Online download statistics by month:

Online download statistics by month: October 2020 to April 2024

AbstractFullPdf
Oct 2020422415159
Nov 2020278271109
Dec 202012312333
Jan 202110910548
Feb 2021676718
Mar 2021787624
Apr 2021979640
May 2021929152
Jun 2021758045
Jul 2021595928
Aug 2021434315
Sep 2021566335
Oct 20219410571
Nov 2021495937
Dec 2021354525
Jan 2022587030
Feb 2022526531
Mar 2022506033
Apr 2022597022
May 2022474625
Jun 2022666832
Jul 2022403623
Aug 2022484514
Sep 2022535021
Oct 2022545432
Nov 202243429
Dec 202228298
Jan 2023464529
Feb 202338387
Mar 2023545113
Apr 2023403920
May 2023383633
Jun 2023575617
Jul 2023404013
Aug 2023272811
Sep 2023454514
Oct 2023595721
Nov 2023484914
Dec 2023484413
Jan 2024424222
Feb 2024363613
Mar 2024363618
Apr 2024383328
Total296730081305